TOPX Network DrinksEmpower your career - a female perspective
Ellen Lefever| General Counsel, AgomAb Therapeutics
Ellen Lefever| General Counsel, AgomAb Therapeutics
Ellen Lefever joined Agomab as General Counsel in 2021. She is responsible for the company’s legal affairs and advises on the company’s transactional matters. Ellen also acts as secretary to the Board of Directors. She previously served as Deputy General Counsel at Galapagos, where she led the corporate law department. Prior to this, she worked at corporate law firms Linklaters, Simpson, Thacher & Bartlett and Eubelius where she focused on M&A and capital markets transactions. Ellen holds an LL.M. in Corporate Governance & Practice from Stanford Law School and a master’s degree in law from the University of Leuven.
AgomAb Therapeutics
AgomAb is developing molecular therapies for the regeneration of damaged tissues. AgomAb's unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.The AgomAb team has selected the most promising lead antibodies and continues to generate preclinical data that support the use of these antibodies in fibrotic, inflammatory, autoimmune and degenerative diseases. They are committed to advancing these molecules into clinical development in order to improve the lives of patients with debilitating conditions.
AgomAb is developing molecular therapies for the regeneration of damaged tissues. AgomAb's unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.The AgomAb team has selected the most promising lead antibodies and continues to generate preclinical data that support the use of these antibodies in fibrotic, inflammatory, autoimmune and degenerative diseases. They are committed to advancing these molecules into clinical development in order to improve the lives of patients with debilitating conditions.
| Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
| Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | | |
© Copyright 2020 by Hyphen Projects